A Phase IIa. Open-label, Multicenter, Dose-escalation Study to Assess the Tolerability and Pharmacokinetics of ZD4054 (Zibotentan) Given Orally Once Daily in Subjects With Metastatic Prostate Cancer.
Phase of Trial: Phase II
Latest Information Update: 01 Oct 2012
At a glance
- Drugs Zibotentan (Primary)
- Indications Prostate cancer
- Focus Adverse reactions
- Sponsors AstraZeneca
- 10 Jun 2017 Biomarkers information updated
- 02 Mar 2010 Actual patient number (22) added and actual initiation date (June 2003) added as reported by ClinicalTrials.gov.
- 02 Mar 2010 Actual end date (Oct 2005) added as reported by ClinicalTrials.gov.